Know Your Investor: Samsara Biocapital (October’24 Edition)

Shots:

A California-based venture capital fund, Samsara Biocapital partners with medical companies and scientists to infuse cutting-edge innovations in medicines

In 2023, Samsara participated in five funding rounds and invested around $2.3B to add 19 companies to its portfolio

For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com

Founded in 2016, Samsara Biocapital is a Registered Investment Adviser (RIA) venture capital firm based out of Palo Alto, California. The firm comprises scientists, investors, and operators focusing on early-stage, late-stage, and post-IPO companies developing innovative therapies to enhance patient's lives. The firm invests in healthcare, life sciences, oncology, and digital health-focused companies in the United States and has over 70 companies in its diverse portfolio, including both private and public entities like Abaa Therapeutics, Nura Bio, and Acelyrin

In 2023, Samsara participated in five funding rounds comprising PIPE, Series A, B, C, and D series to add Gossamer Bio, Abcuro, Abivax SA, Seismic Therapeutic, IO Biotech, and Syros Pharmaceuticals to its portfolio. In 2023, ElevateBio received the highest funding worth $401M through Series D funding.

In 2023, Samsara invested in 18 companies dedicated to biopharma, followed by one diagnostic company. Samsara focuses on autoimmune, cancer, endocrine/ metabolic, hematology, inflammation, Neurology, ophthalmic, and Pulmonary. The company makes significant investments in technologies leveraging antibodies, artificial intelligence/machine learning, cell therapy, formulation–topical, gene editing/CRISPR, gene therapy, immunotherapy, protein, small molecule and vaccine. Around 36.8% of Samsara Biocapital's total investments in 2023, were made through PIPE, and 26.31% through Series B. The company's top three investments are:

• Series D funding worth $401M to ElevateBio LLC

• PIPE funding worth $212M to Gossamer Bio Inc.

• $200M funding under Series A to CARGO Therapeutics and under Series B to Upstream Biosciences

In 2023, Samsara Biocapital made:

• 3 investments worth $375.7M in Q1

• 4 investments worth $705M in Q2

• 7 investments worth $812M in Q3

• 5 investments worth $409.5M in Q4

The table below depicts the top 5 out of the 19 investments made by Samsara Biocapital:

Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line "Samsara Biocapital" or for early access to complete data for future reports and analysis register here: https://forms.office.com/r/VwFu6aUm80)